GSK plc vs Merck & Company, Inc. — Valuation Comparison 2026
Access all valuation models for GSK vs MRK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MRK scores higher with a 9.8/10 quality rating vs GSK's 8.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing GSK plc (GSK) and Merck & Company, Inc. (MRK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
GSK currently trades at $51.24 with a QOC of 8.7/10, while MRK trades at $119.89 with a QOC of 9.8/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).